Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering and a concurrent private placement. The transactions are expected to generate aggregate gross proceeds of approximately $2.9 million, which the company plans to use for working capital and general corporate purposes.
Under the terms of the agreements, Dyadic will sell 3,625,000 common shares at a price of $0.795 per share in the registered direct offering. In the private placement, the company will issue warrants to purchase an equal number of common shares, priced at $0.005 per warrant, with an exercise price of $0.84 per share. The offerings are expected to close on or about Aug. 14, 2026, subject to customary closing conditions.
Dyadic intends to utilize the net proceeds from the offerings, along with its existing cash, cash equivalents, restricted cash, and investment-grade securities, to support its ongoing operations and strategic initiatives. The company focuses on developing and commercializing scalable, non-animal protein production platforms to address the growing global demand in the life sciences, food and nutrition, and bio-industrial markets. Its proprietary Dapibus™ and C1 expression systems are designed to provide rapid, cost-effective, and flexible manufacturing solutions, enabling customers to create more efficient and sustainable products.
The capital infusion comes at a time when the biotechnology sector is increasingly prioritizing sustainable and scalable production methods. Dyadic's non-animal protein platforms have the potential to significantly impact industries ranging from pharmaceuticals to food production, offering alternatives that are both environmentally friendly and economically viable. This funding will likely accelerate the company's research and development efforts, potentially leading to new partnerships and product advancements.
Aegis Capital Corp. is serving as the exclusive placement agent for the offerings. The company has not disclosed further details about the institutional investor involved.
For more information on the press release, visit https://ibn.fm/od7FJ. To learn more about Dyadic International, Inc., visit https://dyadic.com/.
